These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33553221)

  • 1. Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications.
    Donate-Correa J; Ferri CM; Sánchez-Quintana F; Pérez-Castro A; González-Luis A; Martín-Núñez E; Mora-Fernández C; Navarro-González JF
    Front Med (Lausanne); 2020; 7():628289. PubMed ID: 33553221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory Targets in Diabetic Nephropathy.
    Donate-Correa J; Luis-Rodríguez D; Martín-Núñez E; Tagua VG; Hernández-Carballo C; Ferri C; Rodríguez-Rodríguez AE; Mora-Fernández C; Navarro-González JF
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32046074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.
    Górriz JL; Soler MJ; Navarro-González JF; García-Carro C; Puchades MJ; D'Marco L; Martínez Castelao A; Fernández-Fernández B; Ortiz A; Górriz-Zambrano C; Navarro-Pérez J; Gorgojo-Martinez JJ
    J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.
    Donate-Correa J; Tagua VG; Ferri C; Martín-Núñez E; Hernández-Carballo C; Ureña-Torres P; Ruiz-Ortega M; Ortiz A; Mora-Fernández C; Navarro-González JF
    J Clin Med; 2019 Feb; 8(3):. PubMed ID: 30818852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease.
    Liu C; Yang M; Li L; Luo S; Yang J; Li C; Liu H; Sun L
    Front Physiol; 2022; 13():909569. PubMed ID: 35874522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation in Diabetic Kidney Disease.
    Pérez-Morales RE; Del Pino MD; Valdivielso JM; Ortiz A; Mora-Fernández C; Navarro-González JF
    Nephron; 2019; 143(1):12-16. PubMed ID: 30273931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease.
    Guo J; Liu Z; Gong R
    Clin Sci (Lond); 2019 Jun; 133(12):1321-1339. PubMed ID: 31221822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline for diabetic kidney disease.
    Shan D; Wu HM; Yuan QY; Li J; Zhou RL; Liu GJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006800. PubMed ID: 22336824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease.
    Lu HC; Dai WN; He LY
    Diabetes Metab Syndr Obes; 2021; 14():329-344. PubMed ID: 33519221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of and risk factors for the development and progression of diabetic kidney disease.
    Macisaac RJ; Ekinci EI; Jerums G
    Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S39-62. PubMed ID: 24461729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
    Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
    Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease.
    Matoba K; Takeda Y; Nagai Y; Kawanami D; Utsunomiya K; Nishimura R
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokines in diabetic nephropathy.
    Donate-Correa J; Martín-Núñez E; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    J Diabetes Res; 2015; 2015():948417. PubMed ID: 25785280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.
    Alicic RZ; Johnson EJ; Tuttle KR
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):181-191. PubMed ID: 29580582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Inflammation and Progression of Diabetic Kidney Disease.
    Furuya F; Ishii T; Kitamura K
    Contrib Nephrol; 2019; 198():33-39. PubMed ID: 30991405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms.
    Kawanami D; Takashi Y
    Front Pharmacol; 2020; 11():967. PubMed ID: 32694999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop.
    Zhou Y; Ma XY; Han JY; Yang M; Lv C; Shao Y; Wang YL; Kang JY; Wang QY
    World J Diabetes; 2021 Jan; 12(1):19-46. PubMed ID: 33520106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing the development and progression of diabetic kidney disease: Where do we stand?
    Zagkotsis G; Markou M; Paschou E; Papanikolaou P; Sabanis N
    Diabetes Metab Syndr; 2018 Jul; 12(4):585-590. PubMed ID: 29602760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.